COMPARISON
Dulaglutide vs Liraglutide
5 attributes held for at least one of the two. 4 differ. Each value carries the register it came from and the date that register was read.
Answer
Dulaglutide is authorised or registered in 10 and Liraglutide in 10 of the 10 registers read. Dulaglutide: highest phase Phase 4 (after approval). Liraglutide: highest phase Phase 4 (after approval). 24 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Dulaglutide | Liraglutide | |
|---|---|---|
| Registered trials differs | 144 clinicaltrials.gov · 2026-10-03 | 518 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: TRULICITY openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Liraglutide openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | 2014-11-21 ema · 2026-10-03 | 2009-06-30 ema · 2026-10-03 |
| ATC code differs | A10BJ05 ema · 2026-10-03 | A10BJ02 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Dulaglutide | placebo | Liraglutide | placebo |
|---|---|---|---|---|
| Nausea | 14.5% | 5.5% | 26.4% | 7.4% |
| Diarrhoea | 12.8% | 8.5% | 13.1% | 6.1% |
| Nasopharyngitis | 11.2% | 10.4% | 12.4% | 9.3% |
| Hypoglycaemia | 7.5% | 6.6% | 8.7% | 3.3% |
| Constipation | 7.2% | 4.1% | 8.8% | 3.1% |
| Decreased appetite | 7.1% | 2.2% | 6.6% | 1.2% |
| Urinary tract infection | 10.2% | 9.8% | - | - |
| Back pain | 8.4% | 7.9% | - | - |
| Bronchitis | 7.9% | 8.3% | - | - |
| Arthralgia | 7.3% | 7.6% | - | - |
| Vomiting | - | - | 9.0% | 2.1% |
| Headache | - | - | 8.3% | 5.9% |
| Upper respiratory tract infection | - | - | 6.0% | 4.7% |
| Dyspepsia | - | - | 5.3% | 1.3% |
Trial register Dulaglutide: 11 placebo-controlled trials; Liraglutide: 42. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Dulaglutide side effects · Liraglutide side effects
LEGAL STATUS
Approval in each country read
| Country | Dulaglutide | Liraglutide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
24 registered trials include both
| NCT07787936 | GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry NOT_YET_RECRUITING · updated 2026-08-26 |
|---|---|
| NCT05220917 | Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study ACTIVE_NOT_RECRUITING · updated 2026-08-13 |
| NCT07702461 | Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists RECRUITING · updated 2026-07-24 |
| NCT07027969 | Metabolic Surgery for Atrial Fibrillation Elimination NOT_YET_RECRUITING · updated 2026-04-17 |
| NCT05390892 | PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes RECRUITING · updated 2026-04-13 |
| NCT03498001 | Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging COMPLETED · updated 2026-02-04 |
| NCT07325435 | Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists ACTIVE_NOT_RECRUITING · updated 2026-01-08 |
| NCT07309094 | Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD RECRUITING · updated 2025-12-30 |
| NCT06533527 | Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy COMPLETED · updated 2025-12-05 |
| NCT07188545 | Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Rea ACTIVE_NOT_RECRUITING · updated 2025-09-23 |
| NCT03492580 | A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants COMPLETED · updated 2025-06-25 |
| NCT06581120 | GLP_1 RA Ultrasound Study ENROLLING_BY_INVITATION · updated 2024-11-07 |
| NCT06449235 | Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh UNKNOWN · updated 2024-07-16 |
| NCT05136287 | SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULT COMPLETED · updated 2024-02-28 |
| NCT06120556 | Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes COMPLETED · updated 2024-01-30 |
| NCT05161429 | BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes UNKNOWN · updated 2023-06-22 |
| NCT01511393 | An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC) ENROLLING_BY_INVITATION · updated 2023-06-13 |
| NCT05492305 | Glucagon-like Peptide 1 (GLP1) Receptor Agonists and Mental Health UNKNOWN · updated 2022-09-26 |
| NCT02787551 | Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FR COMPLETED · updated 2022-03-25 |
| NCT04829903 | Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin COMPLETED · updated 2022-03-14 |
The 20 most recently updated are listed.
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.